Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration Management

F. Ryan Prall, MD


November 05, 2020

Figure 1. Wet age-related macular degeneration, illustration.

Clinical studies have established VEGF as a key mediator in ocular angiogenesis. In clinical trials, particular attention has focused on the development of pharmaceutical agents to block or neutralize VEGF expression.

Intravitreal injection with anti-VEGF therapy has become the standard treatment for choroidal neovascular membranes (CNVs) associated with wet AMD. Treatment options in wet AMD include bevacizumab, which is a full-length anti-VEGF antibody; ranibizumab, which is an affinity-matured fragment; pegaptanib; aflibercept, another anti-VEGF trap; and brolucizumab, a single-chain Fv antibody fragment. With the exception of bevacizumab, which is commonly used on an off-label basis, all of the other aforementioned drugs are FDA-approved to treat AMD.

Learn more about the use of VEGF inhibitors in wet AMD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.